Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Pizzagalli DA, et al. Among authors: potter wz. Neuropsychopharmacology. 2021 Nov;46(12):2224. doi: 10.1038/s41386-021-01145-9. Neuropsychopharmacology. 2021. PMID: 34389811 Free PMC article. No abstract available.
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Pizzagalli DA, et al. Among authors: potter wz. Neuropsychopharmacology. 2020 Sep;45(10):1656-1663. doi: 10.1038/s41386-020-0738-4. Epub 2020 Jun 16. Neuropsychopharmacology. 2020. PMID: 32544925 Free PMC article.
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. Krystal AD, et al. Among authors: potter wz. Nat Med. 2020 May;26(5):760-768. doi: 10.1038/s41591-020-0806-7. Epub 2020 Mar 30. Nat Med. 2020. PMID: 32231295 Free PMC article. Clinical Trial.
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.
Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W. Krystal AD, et al. Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.222. Nat Rev Drug Discov. 2018. PMID: 30591715 Free PMC article. No abstract available.
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA. Kantrowitz JT, et al. Among authors: potter wz. Neuropsychopharmacology. 2020 Oct;45(11):1842-1850. doi: 10.1038/s41386-020-0706-z. Epub 2020 May 13. Neuropsychopharmacology. 2020. PMID: 32403118 Free PMC article. Clinical Trial.
327 results